

HIV Diagnostic Testing

This is a PDF version of the following document:

Module 1: [Screening and Diagnosis](#)

Lesson 3: [HIV Diagnostic Testing](#)

You can always find the most up-to-date version of this document at

<https://www.hiv.uw.edu/go/screening-diagnosis/diagnostic-testing/core-concept/all>.

Background

HIV Testing and the Care Continuum

Diagnostic testing is the first step in the HIV care continuum ([Figure 1](#)).^[1] Establishing a diagnosis of HIV has important implications for both HIV treatment and prevention. Accumulating evidence shows that persons with HIV who take antiretroviral therapy and maintain suppressed plasma HIV RNA levels have good clinical outcomes and do not sexually transmit HIV to others.^[2,3,4,5,6] Improving rates of HIV testing and awareness of HIV status is critical because a high proportion of HIV transmissions occur from persons unaware of their HIV diagnosis.^[7] Persons with acute HIV who are unaware of their diagnosis have the highest HIV transmission rates.^[7,8,9,10,11] The Centers for Disease Control and Prevention (CDC) estimated that in 2022, approximately 13% of people with HIV in the United States were unaware of their HIV diagnosis.^[12] Universal testing is also important because individuals who test negative but have a risk of acquiring HIV can be offered HIV preexposure prophylaxis (PrEP).

Approach to HIV Testing in the United States

The CDC and the Association of Public Health Laboratories (APHL) recommend using an HIV-1/2 antigen-antibody immunoassay as the initial screening test, with follow-up testing of reactive samples using an HIV-1/HIV-2 differentiation immunoassay. The latter test can differentiate HIV-1 from HIV-2 and provide antibody confirmation.^[13,14] Indeterminate or ambiguous results based on the initial HIV-1/2 antigen-antibody test and HIV-1/HIV-2 differentiation assay require further evaluation with an HIV nucleic acid test (NAT), such as an HIV-1 RNA polymerase chain reaction (PCR) assay, or rarely an HIV-2 PCR.^[14] This diagnostic algorithm is discussed in detail below in the section Recommended HIV Testing Algorithm. Multiple HIV diagnostic tests are now available, and the testing process can occur in both clinical and nonclinical settings. Although most HIV testing is performed in a laboratory setting, several point-of-care, single-use, rapid tests are now available for use in clinical or nonclinical settings. When using point-of-care testing, such as an oral swab or fingerstick blood sample, reactive tests require confirmatory testing with laboratory-based HIV testing.

Timing of Laboratory Markers following HIV Infection

Fiebig Staging System

Laboratory markers appear in a consistent sequence after the acquisition of HIV. The Fiebig staging system defines six stages of early HIV infection that occur after the eclipse phase and these stages range from the emergence of HIV RNA (Stage I) to full Western blot reactivity (Stage VI) ([Figure 2](#)).^[15]

Early HIV Test Reactivity and Terminology

The CDC/APHL document and the Adult and Adolescent ARV Guidelines have defined the following laboratory-based and clinically relevant terms related to acute HIV.^[14,16] Note that some of these terms are not standardized, and alternative terminology, such as primary HIV (instead of acute HIV), is often used ([Figure 3](#)).

- **Eclipse Phase:** The eclipse phase is the initial interval after HIV infection when no existing diagnostic test, including the HIV NAT, is capable of detecting HIV. During this phase, even HIV RNA PCR assays, which are the first tests that can detect HIV following HIV acquisition, are negative because the HIV RNA levels have not yet reached levels detectable by standard laboratory assays. The eclipse phase lasts roughly 8–10 days and may vary based on the sensitivity of the HIV PCR assay used.
- **Window Period:** The HIV seroconversion window period is the interval between HIV acquisition and the first detection of anti-HIV antibodies; the length of the window period varies depending on the specific HIV antibody assay used.
- **Acute HIV:** The term acute HIV (also referred to as primary HIV) typically describes the interval between the detection of HIV RNA and the detection of anti-HIV antibodies. During acute HIV infection, the HIV RNA is always detectable, and the HIV p24 antigen is often positive. People with acute HIV may have an abrupt onset of clinical symptoms.
- **Recent Infection:** The term recent infection usually describes the period after acute HIV when anti-HIV antibodies are developing, up to 6 months after HIV acquisition.
- **Early Infection:** Early infection is generally used to describe both acute and recent HIV time periods, which extend out to 6 months after HIV acquisition.
- **Established HIV Infection:** The term established infection refers to the time after early HIV, during which anti-HIV IgG antibody responses have fully developed.

Timing of HIV Test Reactivity with Modern Assays

The CDC/APHL document, based on several CDC-related studies, outlines the sequence of contemporary laboratory markers that become reactive following the acquisition of HIV ([Figure 4](#)).^[17,18] Following HIV acquisition, HIV RNA becomes detectable on standard laboratory tests approximately 8–10 days after infection.^[15] The next marker to appear is the p24 antigen, which typically reaches detectable levels about 7 days after the emergence of HIV-1 RNA. A positive p24 antigen test usually occurs when HIV-1 RNA levels exceed 20,000–30,000 copies/mL.^[14,16] Next, approximately 5 days later, the enzyme immunoassay (EIA) IgM antibody test becomes reactive and the IgM antibodies are gradually replaced by IgG antibodies, which appear 2 to 6 weeks after initial HIV RNA detection.^[15]

Tests Used for the Diagnosis of HIV

Updated Nomenclature for HIV Serologic Tests

In the United States, HIV serologic tests have historically been categorized as first-, second-, third-, fourth-, and fifth-generation tests, based on evolving techniques and significant improvement in assay sensitivity.[19,20] With many of the new and improved HIV assays, a clear distinction between the HIV generations has blurred, and thus, use of the HIV test “generation” nomenclature is no longer routinely used.[21] Nevertheless, from a conceptual standpoint, it is still important to understand the framework of generations of HIV tests. The first- and second-generation antibody assays are now referred to as IgG-sensitive tests, third-generation assays as IgM/IgG-sensitive tests; fourth-generation tests are antigen-antibody immunoassays that provide a combined result based on detection of any component of the test (p24 antigen, HIV-1 antibodies, or HIV-2 antibodies); and fifth-generation tests are antigen-antibody immunoassays that can differentiate between HIV-1 antibodies, HIV-2 antibodies, and the p24 antigen (Figure 5).[14,19,20,22] Further, the use of the term “rapid” HIV test is less preferable than the term “point-of-care” HIV test, since several instrumented, laboratory-based tests now have the capacity to generate HIV test results rapidly (in less than one hour). Instead, it is preferred to describe HIV serologic tests as either laboratory-based or point-of-care.[20,21]

Summary of Test Methods used for Diagnosing HIV

The major tests used as screening tests for diagnosing HIV are (1) HIV antigen-antibody laboratory-based tests, (2) HIV antigen-antibody point-of-care tests, (3) HIV antibody laboratory-based tests, and (4) HIV antibody point-of-care tests.[23,24] There are also two FDA-approved HIV antibody tests for use and interpretation at home.[25] Further, HIV diagnostic testing includes HIV-1/2 differentiation assays and HIV nucleic acid tests (NATs). The NAT testing includes options for qualitative HIV RNA or proviral DNA PCR assays or a quantitative RNA PCR assay, commonly referred to as a viral load test. The following summarizes the major FDA-approved HIV screening and differentiation assays.[13,20,24] Detailed lists of specific assays for these tests are provided in the CDC document that summarizes FDA-approved HIV tests.[24]

HIV Antigen-Antibody Laboratory-Based Tests

The HIV antigen-antibody laboratory-based immunoassays are the preferred screening tests for HIV. These immunoassays detect HIV-1 p24 (capsid) antigen and antibodies (IgM and IgG) to HIV-1 and HIV-2 (Figure 6).[14,20,26] The HIV-1/2 antigen-antibody immunoassays detect HIV significantly earlier than laboratory-based antibody tests, point-of-care antigen-antibody tests, and point-of-care HIV antibody tests.[20,27] All reactive HIV-1/2 antigen-antibody tests require confirmatory testing. None of the HIV-1/2 antigen-antibody immunoassays detect the HIV-2 core antigen (p26), but cross-reactivity to HIV-1 p24 antigen can occur in persons with HIV-2.

- Laboratory-based HIV-1/2 antigen-antibody immunoassays detect p24 antigen, HIV-1 antibody (typically groups O and M), and/or HIV-2 antibody. Most of the approved and available assays give a reactive result when any of these components are detected, but they cannot distinguish which component was identified. Only a few of the assays can distinguish p24 antigen from HIV-1 antibody and/or HIV-2 antibody; these assays report an overall reactive result and a sub-result that identifies specific test component reactivity.
- Antigen-antibody immunoassays use various laboratory testing methods, but are similar in that they can all be performed in a laboratory setting and completed in under 1 hour (and some in 20-30 minutes). Antigen-antibody combination immunoassays demonstrate excellent sensitivity (approaching 100%) and high specificity (typically 99.8-100%) for detecting HIV infection. These performance characteristics are better than point-of-care tests, which have more false-negative results (due to a longer window period) and a higher rate of false-positive results.

HIV Antigen-Antibody Point-of-Care Tests

The point-of-care HIV-1/2 antigen-antibody test is a single-use, rapid test that can detect HIV-1 p24 antigen, antibodies to HIV-1, and antibodies to HIV-2.[28] This assay is a point-of-care, single-use, rapid test that can detect HIV-1 p24 antigen, antibodies to HIV-1, and antibodies to HIV-2.[28,29] This assay can differentiate HIV-1 p24 antigen from HIV antibody, but it does not differentiate HIV-1 and HIV-2 antibodies.[30] The sensitivity of this assay for acute or very recent HIV infection is lower than laboratory-based HIV-1/2 antigen-antibody assays.[31,32,33] With this assay, the use of fingerstick whole blood specimens is not as sensitive as with plasma samples.[34]

HIV Antibody Laboratory-Based Tests

The HIV enzyme immunoassay (EIA) antibody test for HIV diagnosis was first licensed in the United States in 1985.[19] For more than 20 years, HIV antibody tests were widely used as the initial laboratory diagnosis test in the HIV testing algorithm. Since 2014, however, the use of HIV antibody tests as an initial screening test has been replaced by HIV antigen-antibody assays.[13,14] A reactive HIV antibody test always requires further confirmatory testing with another HIV assay.[14] Most current laboratory-based HIV antibody tests are IgM/IgG-sensitive assays (as opposed to IgG-only assays) and can detect HIV IgM antibodies at approximately 23 to 25 days after HIV acquisition.[20] The CDC considers these HIV antibody tests to have a window period of 90 days (even the IgM/IgG-sensitive assays); in this context, a negative HIV EIA test 90 days after a possible HIV exposure is considered to effectively rule out HIV acquisition from that exposure.[21]

HIV Antibody Single-Use, Point-of-Care Tests

Single-use, point-of-care HIV test kits include self-contained testing reagents and materials and typically can yield a test result within 40 minutes.[19,24,35] There are multiple point-of-care (rapid) tests that the CDC identifies as suitable for use in clinical and nonclinical settings.[] Most of these tests detect antibodies to HIV-1 and HIV-2. These antibody test results are either reactive or nonreactive. Hence, none of the currently used point-of-care antibody tests can differentiate HIV-1 from HIV-2. Single-use, point-of-care rapid antibody tests are less sensitive than laboratory-based antigen-antibody tests for detecting early HIV.[37,38,39,40] Among the point-of-care tests, oral fluid samples have shown the most problems with false-negative and false-positive test results. All positive point-of-care HIV test results are considered to be a presumptive positive test and require further supplemental testing for confirmation of HIV.[14] Single-use, point-of-care testing is primarily used for testing (1) in emergency room encounters where follow-up might be problematic, (2) women in labor who had no HIV testing performed during their pregnancy, (3) in an occupational exposure to HIV when immediate results may be needed, and (4) in other clinical settings where a low likelihood of follow-up for HIV test results is anticipated.[19,41,42]

HIV-1/2 Supplemental (Differentiation) Assays

Several tests can distinguish HIV-1 from HIV-2 and these tests are referred to as supplemental or differentiation assays.[43,44] Results may indicate reactivity for HIV-1, reactivity for HIV-2, or reactivity for both in cases of HIV-1/HIV-2 coinfection. Differentiating HIV-1 and HIV-2 is important to avoid misclassification of HIV infection.[13,14] These tests, which are antibody immunoassays, are also used to confirm an initial reactive HIV-1/2 antigen antibody test.

HIV-1 Western Blot Laboratory Tests

The HIV-1 Western blot has been largely replaced by more sensitive and specific HIV diagnostic tests. When used, the HIV-1 Western blot can detect human antibodies that react to HIV-1 proteins that originate from three HIV-1 gene regions: *env* (gp41, gp120/160), *pol* (p31, p51, p66), and *gag* (p15, p17, p24, p55) (Figure 7).[45] The HIV Western blot typically becomes positive after about 5 to 6 weeks following HIV acquisition; as more protein bands become detectable, the Western blot typically evolves from a pattern of negative, to

indeterminate, to positive.[45]

HIV Self Testing

When HIV testing is performed by the person undergoing testing, it is referred to as self testing or in-home testing. With HIV self-testing, the specimen is collected at home (or in another private location) and mailed in for testing. Commercially available home tests provide individuals with an option for anonymous HIV testing. Self-testing may be preferable for some people who are reluctant to undergo HIV testing in medical settings.[46,47] Studies have shown that self-testing is feasible and acceptable for persons undergoing testing,[47,48,49,50,51] though several concerns persist, including (1) the cost of the test, (2) low sensitivity for detecting recent HIV acquisition, (3) lack of appropriate counseling and confirmatory testing for a positive test result, and (4) insufficient resources for linkage to care for persons with a positive test or linkage to HIV PrEP services for people with a negative test result.

HIV Nucleic Acid Diagnostic Laboratory Tests

In the United States, HIV nucleic acid tests, including qualitative HIV RNA and quantitative HIV RNA assays, are used as part of the HIV diagnostic algorithm.[13] Given the very low limit of detection of most quantitative HIV RNA assays, many clinicians now use quantitative HIV RNA tests (also known as viral load tests) for diagnostic purposes, rather than FDA-approved qualitative HIV RNA assays. The quantitative tests are more widely available than the qualitative tests, as they are routinely used in the clinical management of persons with established HIV.[19,52] The HIV NAT tests are not typically used as an initial HIV screening test due to high cost, technical complexity, and failure to detect HIV RNA in elite controllers (the approximately 0.5% of individuals with HIV who maintain undetectable HIV RNA levels without antiretroviral therapy).[53] The diagnostic HIV NATs are primarily used in the following situations.[13,54,55]

- In the CDC/APHL HIV diagnostic algorithm to evaluate discordant results when a specimen has a reactive HIV-1/2 antigen-antibody immunoassay, but a nonreactive or indeterminate HIV-1/HIV-2 differentiation assay. In this setting, a positive HIV NAT may indicate possible acute infection.
- When a high suspicion of acute HIV exists, and the initial HIV-1/2 antigen-antibody immunoassay is nonreactive. In this scenario, a nonreactive HIV-1/2 antigen-antibody immunoassay and a positive HIV NAT confirm the diagnosis of acute (primary) HIV.
- As part of screening for HIV infection, in addition to an antigen-antibody assay, for persons planning to start or already receiving HIV PrEP.

Recommended HIV Testing Algorithm

The Centers for Disease Control and the Association of Public Health Laboratories (CDC/APHL) HIV testing algorithm recommends using an HIV-1/2 antigen-antibody immunoassay as the initial HIV test, with a reactive initial test results followed by an HIV-1/2 differentiation immunoassay ([Figure 8](#)).[\[13,14,56\]](#) This HIV testing algorithm will detect HIV in most people with recent HIV-1 infection and virtually all people with chronic (HIV-1 and/or HIV-2) infection.[\[13,14\]](#) Although the use of this algorithm enhances earlier detection of acute HIV-1 infection than with HIV antibody testing alone, it does not accurately detect HIV immediately following HIV acquisition (during the eclipse phase).[\[57\]](#) The rationale for including HIV-2 testing in the algorithm is that HIV-2 infection, though uncommon in the United States, significantly differs from HIV-1 with respect to natural history and response to antiretroviral treatment regimens. Indeterminate or ambiguous results based on the initial HIV-1/2 antigen-antibody test and HIV-1/HIV-2 differentiation assay require further evaluation with an HIV nucleic acid test (NAT). From a practical standpoint, the same patient blood sample can be used to perform the initial screening test and the HIV differentiation assay.

Initial Test in Algorithm

The recommended initial test in the CDC/APHL HIV testing algorithm should be a laboratory-based HIV-1/2 antigen-antibody immunoassay; these tests can detect antibodies to HIV-1, antibodies to HIV-2, and HIV-1 p24 antigen.[\[13,14\]](#) A reactive HIV-1/2 antigen-antibody immunoassay requires confirmation and differentiation of HIV-1 from HIV-2 infection.[\[13,14\]](#) A person with a nonreactive HIV-1/2 antigen-antibody immunoassay is considered not to have HIV infection, unless a recent exposure to HIV has occurred. If no recent exposure to HIV has occurred, further HIV testing is not required for evaluation of current HIV status.[\[13,14\]](#) A CDC study evaluated the reactivity of HIV tests in specimens from individuals with HIV-1 seroconversion and showed that an HIV-1/2 antigen-antibody immunoassay was reactive in 75% at 24 days and in 99% at 44.3 days ([Figure 9](#)).[\[27\]](#) Accordingly, a nonreactive laboratory-based HIV-1/2 antigen-antibody immunoassay virtually excludes HIV infection if 45 days or more have passed since the last possible exposure to HIV.[\[21\]](#) In situations where it is not feasible to perform a laboratory-based initial HIV-1/2 antigen-antibody immunoassay, a point-of-care HIV-1/2 antigen-antibody test can be used as the initial test in the HIV diagnostic laboratory algorithm.[\[58\]](#)

Differentiation Assay

If the initial screening HIV-1/2 antigen-antibody immunoassay is reactive, a second (supplemental) HIV test is needed to confirm the initial test and to differentiate whether the infection is caused by HIV-1, HIV-2, or both.[\[13,24,56,59\]](#) For this purpose, the CDC algorithm recommends using an HIV-1/HIV-2 antibody supplemental (differentiation) assay. Samples that are reactive with the HIV-1/2 antigen-antibody immunoassay and the HIV supplemental assay are considered positive for HIV and should be classified as HIV-1, HIV-2, or HIV-1 and HIV-2.[\[13\]](#) Specimens that are reactive on the initial HIV-1/2 antigen-antibody immunoassay but either indeterminate or nonreactive on the differentiation assay require further testing with an HIV-1 NAT (qualitative or quantitative RNA assay) to evaluate the possibility of acute HIV (false-negative differentiation assay due to the window period) versus a false-positive HIV-1/2 antigen-antibody test. In this situation, if the NAT is positive for HIV-1, the person is likely to have acute HIV-1 infection.

HIV Nucleic Acid Testing

If the initial HIV-1/2 antigen-antibody immunoassay is reactive, but the HIV-1/HIV-2 differentiation assay is nonreactive, further testing with an HIV-1 NAT should be performed.[\[13\]](#) This is generally accomplished by drawing a sample for a qualitative or quantitative HIV-1 RNA assay, unless the individual has a substantial risk for HIV-2 infection or known exposure to HIV-2, in which case an HIV-2 RNA assay should be added. If both the HIV-1/2 antigen-antibody immunoassay and the HIV-1/HIV-2 differentiation assay are reactive, then quantitative HIV RNA testing (viral load) is indicated—HIV-1 quantitative or HIV-2 quantitative, depending on whether HIV-1 or HIV-2 is identified on the differentiation assay.

Interpretation of Test Results

- If the HIV-1/2 antigen-antibody immunoassay is nonreactive, then the interpretation is no infection with HIV-1 or HIV-2, unless the individual undergoing testing has acquired HIV within the past 45 days. If acute HIV is suspected, then perform an HIV-1 NAT.
- If the HIV-1/2 antigen-antibody immunoassay is reactive and the HIV-1/HIV-2 differentiation assay result is reactive for HIV-1 and nonreactive for HIV-2, then conclude the person has HIV-1 infection.
- If the HIV-1/2 antigen-antibody immunoassay is reactive and the HIV-1/HIV-2 differentiation assay result shows nonreactive HIV-1 and reactive HIV-2, then conclude the patient has HIV-2 infection.
- If the HIV-1/2 antigen-antibody immunoassay is reactive and the HIV-1/HIV-2 differentiation assay result shows reactive HIV-1 and reactive HIV-2, then conclude the patient has HIV-1 and HIV-2 coinfection.
- If the HIV-1/2 antigen-antibody immunoassay is reactive and the HIV-1/HIV-2 differentiation assay is nonreactive or shows HIV-1 indeterminate in conjunction with a nonreactive HIV-2, then several possibilities exist. In this scenario, follow-up testing with HIV NAT is indicated. If the HIV NAT is positive, the patient has acute HIV-1. If the HIV-1 NAT is negative, the most probable scenario is that the initial reactive immunoassay result was a false-positive result, and the individual undergoing testing does not likely have HIV-1 or HIV-2. Alternatively, in a person with risk factors for acquiring HIV-2, these test results could theoretically indicate acute HIV-2. Follow-up additional testing with HIV-2 NAT should be considered if an individual has epidemiologic risk factors for exposure to HIV-2.

Performance of Diagnostic Tests

The principles that define a good screening test are not unique to HIV infection and apply to medical screening in general. An ideal screening test will accurately identify individuals with the clinical condition of interest without mistakenly diagnosing those who do not have the condition. In addition, the use of screening tests is most effective when limited to conditions for which there exists available, effective treatment that can directly target the disease and improve prognosis and outcomes.[60]

False-Negative HIV Tests

A false-negative HIV test result refers to a negative HIV test result in a person who actually has HIV (Figure 10). A false-negative HIV antigen-antibody test result most often occurs when performing HIV testing in a person with acute HIV (the p24 antigen usually becomes reactive by day 17) or when a person received potent antiretroviral therapy very early after HIV acquisition.[61,62,63] Additional causes of false-negative results include failure to generate anti-HIV antibodies due to defects in immunity, acquisition of HIV while receiving HIV PrEP, hypogammaglobulinemia, recent receipt of potent immunosuppressant medications, or laboratory error.[64,65,66,67,68] In adults with chronic HIV, the loss of HIV antibodies (seroreversion) is exceedingly rare.[69] A false-negative HIV NAT can occur in the first 8–10 days after HIV acquisition during the eclipse phase and in those rare persons with chronic HIV who inherently have very strong immunologic control of HIV (elite controllers) and thus may have undetectable HIV RNA levels in the absence of antiretroviral therapy.

False-Positive HIV Tests

A false-positive HIV test result is defined as a positive HIV test result in a person who does not have HIV (Figure 11). A false-positive HIV test may occur due to polyclonal cross-reactivity, which is more common in the setting of pregnancy, recent inoculation with influenza vaccine (or other vaccines), autoimmune disorders, receipt of an investigational HIV-1 vaccine, receipt of gamma globulin, prior blood transfusions, human T-lymphotropic virus (HTLV) infection, recent viral infection (including COVID-19), collagen vascular diseases, and laboratory errors.[70,71] Recently, several reports have described false-positive HIV NATs in persons who received chimeric antigen receptor (CAR) T-cell therapy, due to the lentivirus used as the vector in manufacturing these individualized therapies; in these cases, the lentivirus vector used had incorporated a plasmid that contained part or all of the HIV *gag* sequence.[72] When trying to determine whether a person's HIV screening test result is accurate, the pretest probability—the likelihood before the test was performed that the patient has HIV—can help with interpretation. Further, the likelihood of an accurate HIV test result correlates directly with the prevalence of HIV in the testing community: the proportion of false-positive tests is higher in populations with low HIV prevalence (even if the screening test is highly sensitive and specific), whereas the proportion of false-negative tests is lower.[73]

Special Diagnostic Situations

Diagnosis of Acute HIV-1

The laboratory diagnosis of acute HIV-1 infection is most reliably made with a positive HIV RNA (or HIV-1 p24 antigen) with a concomitant negative HIV antibody assay; note that with very early acute HIV infection, the p24 antigen assay may be negative ([Figure 12](#)).[\[16,74,75\]](#) Use of HIV-1/2 antigen-antibody immunoassays will detect HIV about 17 days after HIV acquisition, which is significantly sooner than with HIV laboratory-based HIV antibody tests, all point-of-care HIV tests, and in-home HIV tests.[\[18,57,76,77\]](#) Even when using HIV-1/2 antigen-antibody immunoassays, the initial laboratory testing will fail to detect some individuals who have very early acute HIV infection. Thus, for individuals in whom initial HIV-1/2 antigen-antibody testing is nonreactive, but acute HIV is strongly suspected, HIV NAT (i.e., HIV RNA testing) should be performed. Because HIV RNA levels are typically very high in persons with acute retroviral syndrome, an HIV NAT is uniformly positive at this stage of infection. Ideally, if acute HIV is suspected, a quantitative RNA assay (as opposed to a qualitative RNA assay) should be ordered since HIV RNA levels are typically very high at this stage.

Diagnosing HIV In Persons Receiving HIV PrEP

The diagnostic accuracy and timing of early HIV infection in persons who acquire HIV while taking HIV PrEP may result in atypical laboratory patterns, such as delayed seroconversion, indeterminate results on HIV differentiation assays, low-level HIV RNA levels, or HIV RNA levels below the limit of the assay, even in persons with acute or early HIV.[\[78\]](#) Multiple studies have reported false-negative, ambiguous, or delayed diagnosis with HIV test results in persons taking HIV PrEP.[\[20,67,78,79\]](#) Problems with false-negative testing are greater in this setting when using point-of-care tests; thus, laboratory-based HIV testing is recommended when monitoring persons receiving HIV PrEP.[\[20,54\]](#) In situations where results are ambiguous or confusing, clinical consultation is recommended.

Diagnosis of HIV in Infants and Children Exposed to HIV

The CDC/APHL HIV diagnostic algorithm does not address HIV diagnostic testing of infants and children exposed to HIV.[\[13,14\]](#) To diagnose HIV among infants younger than 18 months of age, the Pediatric ART Guidelines recommend using a virologic assay (HIV NAT) that directly detects HIV RNA or HIV DNA (either quantitative or qualitative tests can be used). This issue is addressed in detail in the section Diagnosis of HIV in Infants and Children in the lesson [HIV in Infants and Children](#).

Diagnosis of HIV-2

The CDC/APHL HIV diagnostic algorithm improves HIV-2 detection by using an HIV-1/HIV-2 differentiation assay as the second step of the algorithm (following the initial HIV-1/2 antigen-antibody immunoassay).[\[13,14,80\]](#) Confirmation of HIV-2 infection can be challenging since HIV-1 RNA assays do not reliably detect or quantitate HIV-2. More recently, quantitative HIV-2 RNA assays have become available through the University of Washington Department of Laboratory Medicine ([HIV-2 RNA Quantitation](#)) and the New York State Department of Health ([HIV-2 Nucleic Acid Testing](#), which includes HIV-2 qualitative or quantitative options).[\[81\]](#) It is important to note that many individuals with HIV-2 have undetectable HIV-2 RNA levels without antiretroviral treatment. Thus, in certain epidemiological settings (e.g., a person with risk factors for HIV-2 acquisition), a positive screening HIV-1/2 antigen-antibody test followed by a positive HIV-2 antibody on the differentiation assay should be considered diagnostic for HIV-2 infection, even if plasma HIV-2 RNA is undetectable with an HIV-2 RNA assay.[\[13,14\]](#)

Delivering Test Results

Follow-Up for Test Results

The use of multiple modalities for HIV testing and delivery of HIV test results has helped to optimize this process. In particular, delivery of HIV test results by telephone has been found to be both effective and acceptable, and increases the number of people who receive their test results.[\[82,83\]](#) In addition, the use of point-of-care tests, which provide a result at the same visit and augment the capacity to run tests quickly at mobile and community sites, provides an opportunity for real-time delivery of test results.[\[84\]](#)

Implementation of point-of-care tests in outreach and community settings enhances testing of people at risk of acquiring HIV who may not regularly have access to medical care. The availability of self-testing also increases the proportion of persons who undergo HIV testing and can immediately see their test result. That said, a positive self-test result always requires confirmatory testing, and it remains unclear whether self-testing significantly reduces the number of individuals with undiagnosed HIV.[\[49,85,86\]](#)

Communicating Test Results

The CDC offers practical advice for health care professionals who offer HIV testing in their clinical settings.[\[87\]](#) Health care professionals should deliver results to individuals undergoing HIV testing in a private area and in a direct, neutral tone. The individual delivering the test results should be knowledgeable about HIV, since persons undergoing testing may have questions about HIV, risk of transmission to partners, and disclosure of HIV status to partners. Any individual who receives a positive HIV test result should be linked to HIV care prior to leaving the testing setting and should have a scheduled appointment with an HIV medical provider as soon as possible. Availability of a case manager or social worker familiar with HIV-related resources can aid in the initial discussion and linkage to care. The ability to provide emotional support, medical information, and timely linkage to care is critical when delivering positive HIV results.[\[88\]](#) For persons who test negative for HIV, the medical provider should be prepared to provide HIV prevention counseling to help the individual remain HIV negative, including discussion of and referral for HIV PrEP, if indicated.

Summary Points

- Laboratory markers of HIV infection (HIV RNA, p24 antigen, anti-HIV IgM antibody, anti-HIV IgG antibody) appear in a consistent sequence and are the basis for all the HIV diagnostic tests.
 - The CDC/APHL algorithm recommends initial testing with an HIV-1/2 antigen-antibody immunoassay, with reflex of reactive tests to an HIV-1/2 differentiation assay. Testing for HIV RNA should be done in cases where the initial test is reactive, but the differentiation assay is either nonreactive or indeterminate.
 - Compared to previous screening algorithms, the current algorithm is more likely to detect acute HIV-1 and more accurately differentiate HIV-1 from HIV-2 infection.
 - False-negative HIV screening test results can occur during acute HIV; false-positive HIV screening test results may occur due to laboratory errors and rarely from cross-reactivity with other antibodies, such as during pregnancy, in persons who have an autoimmune condition, or following recent vaccine administration.
 - Testing for HIV RNA may identify very early HIV infection (HIV RNA tests may be positive up to a week sooner than the antigen-antibody tests), but HIV RNA is typically not detected in the first 10 days after induction during the eclipse phase.
 - Single-use, point-of-care HIV tests and self-testing are additional options to help facilitate HIV screening and detection. A reactive result on a point-of-care or self-test should be considered a presumptive positive result and requires further testing.
 - Challenges may occur with the diagnostic evaluation of acute HIV, when evaluating infants and children exposed to HIV, and in persons receiving HIV PrEP. Clinical consultation is recommended if a person has been exposed to HIV or there is suspicion or risk for HIV, yet HIV test results are ambiguous or indeterminate.
-
- Diagnostic testing for HIV should ideally link persons who test negative to appropriate preventive care and those who test positive to HIV treatment services.

Citations

1. Cheever LW. Engaging HIV-infected patients in care: their lives depend on it. Clin Infect Dis. 2007;44:1500-2.
[\[PubMed Abstract\]](#) -
2. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
[\[PubMed Abstract\]](#) -
3. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795-807.
[\[PubMed Abstract\]](#) -
4. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373:808-22.
[\[PubMed Abstract\]](#) -
5. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795-807.
[\[PubMed Abstract\]](#) -
6. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375:830-9.
[\[PubMed Abstract\]](#) -
7. Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital Signs: HIV transmission along the continuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019;68:267-72.
[\[PubMed Abstract\]](#) -
8. Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009;23:1792-4.
[\[PubMed Abstract\]](#) -
9. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS. 2007;21:1625-9.
[\[PubMed Abstract\]](#) -
10. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785-92.
[\[PubMed Abstract\]](#) -
11. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687-93.
[\[PubMed Abstract\]](#) -
12. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2018–2022. HIV Surveillance Supplemental Report. 2024;29(No. 1):1-131. Published May 2024 (revised February 7, 2025).
[\[CDC\]](#) -
13. Centers for Disease Control and Prevention and Association of Public Health Laboratories. 2018 Quick reference guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens.

Published January 27, 2018.

[\[CDC\]](#) -

14. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Published June 27, 2014.
[\[CDC\]](#) -
15. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS*. 2003;17:1871-9.
[\[PubMed Abstract\]](#) -
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Special Populations. Early (Acute and Recent) HIV Infection. September 12, 2024.
[\[HIV.gov\]](#) -
17. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. *J Clin Virol*. 2011;52 Suppl 1:S17-22.
[\[PubMed Abstract\]](#) -
18. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. *J Clin Microbiol*. 2008;46:1588-95.
[\[PubMed Abstract\]](#) -
19. Branson BM. State of the art for diagnosis of HIV infection. *Clin Infect Dis*. 2007;45 Suppl 4:S221-5.
[\[PubMed Abstract\]](#) -
20. Hurt CB, Nelson JAE, Hightow-Weidman LB, Miller WC. Selecting an HIV Test: A Narrative Review for Clinicians and Researchers. *Sex Transm Dis*. 2017;44:739-46.
[\[PubMed Abstract\]](#) -
21. Delaney KP, Wesolowski LG, Owen SM. The Evolution of HIV Testing Continues. *Sex Transm Dis*. 2017;44:747-9.
[\[PubMed Abstract\]](#) -
22. Branson BM, Mermin J. Establishing the diagnosis of HIV infection: new tests and a new algorithm for the United States. *J Clin Virol*. 2011;52 Suppl 1:S3-4.
[\[PubMed Abstract\]](#) -
23. U.S. Food and Drug Administration. Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays.
[\[FDA\]](#) -
24. Centers for Disease Control and Prevention. FDA-approved HIV tests.
[\[CDC\]](#) -
25. Daskalakis D. HIV diagnostic testing: evolving technology and testing strategies. *Top Antivir Med*. 2011;19:18-22.
[\[PubMed Abstract\]](#) -
26. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. *Clin Infect Dis*. 2017;64:53-9.

[\[PubMed Abstract\]](#) -

27. U.S. Food and Drug Administration. Alere Determine HIV-1/2 Ag/Ab Combo.
[\[U.S. FDA\]](#) -
28. Abbott Diagnostics. Determine HIV-1/2 Ag/Ab Combo.
[\[Abbott Diagnostics\]](#) -
29. Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol. 2013;58 Suppl 1:e54-8.
[\[PubMed Abstract\]](#) -
30. Parker MM, Bennett SB, Sullivan TJ, et al. Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with algorithm-defined acute HIV-1 infection specimens. J Clin Virol. 2018;104:89-91.
[\[PubMed Abstract\]](#) -
31. Duong YT, Mavengere Y, Patel H, et al. Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland. J Clin Microbiol. 2014;52:3743-8.
[\[PubMed Abstract\]](#) -
32. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis. 2012;205:528-34.
[\[PubMed Abstract\]](#) -
33. Masciotra S, Luo W, Westheimer E, et al. Performance evaluation of the FDA-approved Determine™ HIV-1/2 Ag/Ab Combo assay using plasma and whole blood specimens. J Clin Virol. 2017;91:95-100.
[\[PubMed Abstract\]](#) -
34. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS. 2006;20:1655-60.
[\[PubMed Abstract\]](#) -
35. Pilcher CD, Louie B, Facente S, et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One. 2013;8:e80629.
[\[PubMed Abstract\]](#) -
36. Stekler JD, O'Neal JD, Lane A, et al. Relative accuracy of serum, whole blood, and oral fluid HIV tests among Seattle men who have sex with men. J Clin Virol. 2013;58 Suppl 1:e119-22.
[\[PubMed Abstract\]](#) -
37. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49:444-53.
[\[PubMed Abstract\]](#) -
38. Stekler JD, Ure G, O'Neal JD, et al. Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM. J Clin Virol. 2016;76:8-13.
[\[PubMed Abstract\]](#) -
39. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875-92.
[\[PubMed Abstract\]](#) -

40. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329-32.
[\[PubMed Abstract\]](#) -
41. U.S. Food and Drug Administration. Multispot HIV-1/HIV-2 Rapid Test.
[\[U.S. FDA\]](#) -
42. U.S. Food and Drug Administration. Geenius HIV 1/2 Supplemental Assay.
[\[U.S. FDA\]](#) -
43. Centers for Disease Control (CDC). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38(Suppl 7):1-7.
[\[MMWR\]](#) -
44. Carballo-Diéguez A, Frasca T, Dolezal C, Balan I. Will gay and bisexually active men at high risk of infection use over-the-counter rapid HIV tests to screen sexual partners? J Sex Res. 2012;49:379-87.
[\[PubMed Abstract\]](#) -
45. Myers JE, El-Sadr WM, Zerbe A, Branson BM. Rapid HIV self-testing: long in coming but opportunities beckon. AIDS. 2013;27:1687-95.
[\[PubMed Abstract\]](#) -
46. Ricca AV, Hall EW, Khosropour CM, Sullivan PS. Factors Associated with Returning At-Home Specimen Collection Kits for HIV Testing among Internet-Using Men Who Have Sex with Men. J Int Assoc Provid AIDS Care. 2016;15:463-9.
[\[PubMed Abstract\]](#) -
47. Myers JE, Bodach S, Cutler BH, Shepard CW, Philippou C, Branson BM. Acceptability of home self-tests for HIV in New York City, 2006. Am J Public Health. 2014;104:e46-8.
[\[PubMed Abstract\]](#) -
48. Frank AP, Wandell MG, Headings MD, Conant MA, Woody GE, Michel C. Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. Arch Intern Med. 1997;157:309-14.
[\[PubMed Abstract\]](#) -
49. Branson BM. Home sample collection tests for HIV infection. JAMA. 1998;280:1699-701.
[\[PubMed Abstract\]](#) -
50. Karris MY, Anderson CM, Morris SR, Smith DM, Little SJ. Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection. J Clin Microbiol. 2012;50:1874-8.
[\[PubMed Abstract\]](#) -
51. Madec Y, Boufassa F, Porter K, et al. Natural history of HIV-control since seroconversion. AIDS. 2013;27:2451-60.
[\[PubMed Abstract\]](#) -
52. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. December 2021:1-108.
[\[CDC\]](#) -

53. Patel RR, Hoover KW, Lale A, Cabrales J, Byrd KM, Kourtis AP. Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74:541-9.
[\[CDC\]](#) -
54. Centers for Disease Control and Prevention (CDC). Technical Update on HIV-1/2 Differentiation Assays. August 12, 2016.
[\[CDC\]](#) -
55. Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis. 2011;205:521-4.
[\[PubMed Abstract\]](#) -
56. Centers for Disease Control and Prevention (CDC). Technical Update: Use of the Determine HIV 1/2 Ag/Ab Combo Test with Serum or Plasma in the Laboratory Algorithm for HIV Diagnosis. October 4, 2017.
[\[CDC\]](#) -
57. Herssens N, Beelaert G, Fransen K. Discriminatory capacity between HIV-1 and HIV-2 of the new rapid confirmation assay Geenius. J Virol Methods. 2014;208:11-5.
[\[PubMed Abstract\]](#) -
58. Croft P, Altman DG, Deeks JJ, et al. The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. BMC Med. 2015;13:20.
[\[PubMed Abstract\]](#) -
59. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis. 2005;40:868-73.
[\[PubMed Abstract\]](#) -
60. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis. 2006;42:700-8.
[\[PubMed Abstract\]](#) -
61. de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. Clin Infect Dis. 2016;63:555-61.
[\[PubMed Abstract\]](#) -
62. Spivak AM, Sydnor ER, Blankson JN, Gallant JE. Seronegative HIV-1 infection: a review of the literature. AIDS. 2010;24:1407-14.
[\[PubMed Abstract\]](#) -
63. Sullivan PS, Schable C, Koch W, et al. Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. AIDS. 1999;13:89-96.
[\[PubMed Abstract\]](#) -
64. Donnell D, Ramos E, Celum C, et al. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS. 2017;31:2007-16.
[\[PubMed Abstract\]](#) -

65. Smith DK, Switzer WM, Peters P, et al. A Strategy for PrEP Clinicians to Manage Ambiguous HIV Test Results During Follow-up Visits. *Open Forum Infect Dis*. 2018;5:ofy180.
[\[PubMed Abstract\]](#) -
66. Padeh YC, Rubinstein A, Shliozberg J. Common variable immunodeficiency and testing for HIV-1. *N Engl J Med*. 2005;353:1074-5.
[\[PubMed Abstract\]](#) -
67. Roy MJ, Damato JJ, Burke DS. Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. *JAMA*. 1993;269:2876-9.
[\[PubMed Abstract\]](#) -
68. Klarkowski D, O'Brien DP, Shanks L, Singh KP. Causes of false-positive HIV rapid diagnostic test results. *Expert Rev Anti Infect Ther*. 2014;12:49-62.
[\[PubMed Abstract\]](#) -
69. Alfie LG, Longueira YS, Pippo M, et al. Increased risk of false-positive HIV ELISA results after COVID-19. *AIDS*. 2023;37:947-50.
[\[PubMed Abstract\]](#) -
70. Theppote AS, Carmack AE, Riedel DJ. False positive HIV testing after T-cell receptor therapy. *AIDS*. 2020;34:1103-1105.
[\[PubMed Abstract\]](#) -
71. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. *BMJ*. 1994;309:102.
[\[PubMed Abstract\]](#) -
72. Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. *Clin Infect Dis*. 2013;57:712-8.
[\[PubMed Abstract\]](#) -
73. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. *J Infect Dis*. 2010;202 Suppl 2:S270-7.
[\[PubMed Abstract\]](#) -
74. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013. *MMWR Morb Mortal Wkly Rep*. 2013;62:489-94.
[\[PubMed Abstract\]](#) -
75. Masciotra S, Smith AJ, Youngpairoj AS, et al. Evaluation of the CDC proposed laboratory HIV testing algorithm among men who have sex with men (MSM) from five US metropolitan statistical areas using specimens collected in 2011. *J Clin Virol*. 2013;58 Suppl 1:e8-e12.
[\[PubMed Abstract\]](#) -
76. Sivay MV, Li M, Piwowar-Manning E, et al. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. *J Acquir Immune Defic Syndr*. 2017;75:271-9.
[\[PubMed Abstract\]](#) -
77. Landovitz RJ, Donnell D, Clement ME, et al. *N Engl J Med*. 2021;385:595-608.
[\[PubMed Abstract\]](#) -
78. Peruski AH, Wesolowski LG, Delaney KP, et al. Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017. *MMWR Morb Mortal Wkly Rep*. 2020;69:63-6.

[\[PubMed Abstract\]](#) -

79. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Considerations for antiretroviral use in special patient populations: HIV-2 infection. December 6, 2023. [\[HIV.gov\]](#) -
80. Bissessor M, Bradshaw CS, Fairley CK, Chen MY, Chow EP. Provision of HIV test results by telephone is both safe and efficient for men who have sex with men. *Int J STD AIDS*. 2017;28:39-44. [\[PubMed Abstract\]](#) -
81. McKinstry LA, Goldbaum GM, Meischke HW. Telephone notification of HIV test results: impact in King County, Washington. *Sex Transm Dis*. 2007;34:796-800. [\[PubMed Abstract\]](#) -
82. Thornton AC, Delpech V, Kall MM, Nardone A. HIV testing in community settings in resource-rich countries: a systematic review of the evidence. *HIV Med*. 2012;13:416-26. [\[PubMed Abstract\]](#) -
83. Rodger AJ, McCabe L, Phillips AN, et al. Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial. *Lancet HIV*. 2022;9:e838-e847. [\[PubMed Abstract\]](#) -
84. Witzel TC, Eshun-Wilson I, Jamil MS, et al. Comparing the effects of HIV self-testing to standard HIV testing for key populations: a systematic review and meta-analysis. *BMC Med*. 2020;18:381. [\[PubMed Abstract\]](#) -
85. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*. 2006;55:1-17. [\[PubMed Abstract\]](#) -
86. Joseph HA, Fasula AM, Morgan RL, et al. "The anticipation alone could kill you": past and potential clients' perspectives on HIV testing in non-health care settings. *AIDS Educ Prev*. 2011;23:577-94. [\[PubMed Abstract\]](#) -

References

- Centers for Disease Control and Prevention (CDC). False-positive oral fluid rapid HIV tests--New York City, 2005-2008. *MMWR Morb Mortal Wkly Rep*. 2008;57:660-5. [\[MMWR\]](#) -
- Centers for Disease Control and Prevention. HIV-2 Infection Surveillance--United States, 1987-2009. *MMWR Morb Mortal Wkly Rep*. 2011;60:985-8. [\[PubMed Abstract\]](#) -
- Chappel RJ, Wilson KM, Dax EM. Immunoassays for the diagnosis of HIV: meeting future needs by enhancing the quality of testing. *Future Microbiol*. 2009;4:963-82. [\[PubMed Abstract\]](#) -
- Curlin ME, Gvetadze R, Leelawiwat W, et al. Analysis of False-Negative Human Immunodeficiency Virus Rapid Tests Performed on Oral Fluid in 3 International Clinical Research Studies. *Clin Infect Dis*. 2017;64:1663-9.

[\[PubMed Abstract\]](#) -

- Ellenberger DL, Sullivan PS, Dorn J, et al. Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons. *J Infect Dis.* 1999;180:1033-42.
[\[PubMed Abstract\]](#) -
- Fernández McPhee C, Álvarez P, Prieto L, et al. HIV-1 infection using dried blood spots can be confirmed by Bio-Rad Geenius™ HIV 1/2 confirmatory assay. *J Clin Virol.* 2015;63:66-9.
[\[PubMed Abstract\]](#) -
- Keating SM, Kassarjian R, Lebedeva M, et al. Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting "Recent" HIV Infection and Calculating Population Incidence. *J Acquir Immune Defic Syndr.* 2016;73:581-8.
[\[PubMed Abstract\]](#) -
- Malloch L, Kadivar K, Putz J, et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I. *J Clin Virol.* 2013;58 Suppl 1:e85-91.
[\[PubMed Abstract\]](#) -
- Manak MM, Jagodzinski LL, Shutt A, et al. Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection. *J Clin Microbiol.* 2019;57:pii: e00757-19.
[\[PubMed Abstract\]](#) -
- Montesinos I, Eykmans J, Delforge ML. Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. *J Clin Virol.* 2014;60:399-401.
[\[PubMed Abstract\]](#) -
- Nasrullah M, Wesolowski LG, Meyer WA 3rd, et al. Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. *AIDS.* 2013;27:731-7.
[\[PubMed Abstract\]](#) -
- Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. *J Acquir Immune Defic Syndr.* 2013;63 Suppl 2:S187-99.
[\[PubMed Abstract\]](#) -

Figures

Figure 1 HIV Care Continuum

Source: Adapted from HRSA. HIV Care Continuum




Figure 2 (Image Series) - Fiebig Classification for Early HIV-1 Infection (Image Series) - Figure 2 (Image Series) - Fiebig Classification for Early HIV-1 Infection

Image 2A: Duration of Stages

Source: Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-9.

Fiebig Laboratory Stages of Early HIV-1 Infection					
Stage	Duration	HIV RNA	p24 Ag	*EIA	Western blot
Eclipse	11.0 days	(-)	(-)	(-)	(-)
I	5.0 days	(+)	(-)	(-)	(-)
II	5.3 days	(+)	(+)	(-)	(-)
III	3.2 days	(+)	(+)	(+)	(-)
IV	5.6 days	(+)	(+)	(+/-)	#Indeterminate pattern
V	69.5 days	(+)	(+/-)	(+)	Reactive, but absence of p31 (<i>pol</i>)
VI	Open-ended	(+)	(+/-)	(+)	Reactive, including p31 (<i>pol</i>)

* EIA = enzyme immunoassay (refers to IgM-sensitive 3rd generation assay)
 # Indeterminate Western blot: presence of HIV-1 specific bands that fail to meet criteria established by US FDA for positive HIV (reactivity to two of the following three bands: p24, gp41, gp120/160)

Figure 2 (Image Series) - Fiebig Classification for Early HIV-1 Infection
Image 2B: Graphic of Stages

Source: Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-9.




Figure 3 (Image Series) - HIV Definitions Related to Early Infection (Image Series) - Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3A: HIV Eclipse Phase

Illustration: David H. Spach, MD




Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3B: HIV Seroconversion Window

Illustration: David H. Spach, MD




Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3C: Acute HIV

Illustration: David H. Spach, MD




Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3D: Recent HIV

Illustration: David H. Spach, MD




Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3E: Early HIV

Illustration: David H. Spach, MD




Figure 3 (Image Series) - HIV Definitions Related to Early Infection
Image 3F: Established HIV

Illustration: David H. Spach, MD




Figure 4 Timing of Positivity for HIV Diagnostic Tests

This graphic shows estimates for the mean number of days for HIV diagnostic tests to become positive after acquisition of HIV.

Abbreviation: POC = point-of-care

Source: modified from Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Published June 27, 2014.





Figure 5 HIV Serologic Tests: HIV Antibody and HIV Antigen-Antibody

Illustration: David H. Spach, MD



**Figure 6 (Image Series) - Laboratory-Based HIV-1/2 Antigen-Antibody Immunoassays (Image Series) - Figure 6 (Image Series) - Laboratory-Based HIV-1/2 Antigen-Antibody Immunoassays
Image 6A: Components of HIV-1/2 Antigen-Antibody Immunoassay**

The HIV-1/2 antigen-antibody immunoassay contains components that will detect HIV-1 p24 antigen, antibodies to HIV-1, and antibodies to HIV-2. The HIV-1 and HIV-2 recombinant proteins vary from assay to assay.

Illustration by David H. Spach, MD




Figure 6 (Image Series) - Laboratory-Based HIV-1/2 Antigen-Antibody Immunoassays
Image 6B: Patient Sample Reacting with Components in HIV-1/2 Antigen-Antibody Immunoassay

In this example, the patient sample contains HIV-1 p24 antigen and anti-HIV antibodies that bind to the HIV-1 p24 capture antibody and the HIV recombinant proteins.

Illustration: David H. Spach, MD




Figure 6 (Image Series) - Laboratory-Based HIV-1/2 Antigen-Antibody Immunoassays
Image 6C: Reactive HIV-1/2 Antigen-Antibody Immunoassay

The HIV-1/2 antigen-antibody immunoassay will turn positive with the presence of one or more of the following: HIV-1 p24 antigen, antibodies to HIV-1, or antibodies to HIV-2. With most of the laboratory-based assays, the positive reaction is nonspecific and thus does not differentiate HIV-1 p24 antigen, antibodies to HIV-1, or antibodies to HIV-2. In addition, most of the assays will not determine whether more than one of these components are present in a positive reaction.

Illustration: David H. Spach, MD




Figure 7 HIV-1 Western blot

This graphic shows the relationship of the HIV-1 genes and products with the corresponding band on the HIV-1 Western blot.

HIV-1 Gene and Product	Band on Western blot
<i>env</i>	
Precursor Protein	gp160
External Glycoprotein	gp120
Transmembrane Protein	gp41
<i>pol</i>	
Reverse Transcriptase	p66
Reverse Transcriptase	p51
Endonuclease	p31
<i>gag</i>	
Gag Precursor	p55
Core	p24
Matrix	p17
Nucleocapsid Precursor	p15




Figure 8 CDC/APHL Recommended Laboratory Testing Algorithm for the Diagnosis of HIV Infection

Abbreviations: CDC/APHL = Centers for Disease Control and the Association of Public Health Laboratories

Source: Centers for Disease Control and Prevention and Association of Public Health Laboratories. 2018 Quick reference guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens. Published January 27, 2018.




Figure 9 Reactivity of HIV-1/2 Antigen-Antibody Immunoassay Following HIV Acquisition

Time course for HIV-1/2 antigen-antibody immunoassay reactivity after HIV acquisition: 25% at day 14, 50% at day 18, 75% at day 24, and 99% after day 44. Thus, a negative test ≥ 45 days after an exposure virtually excludes HIV infection from that exposure.

Source: Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clin Infect Dis. 2017;64:53-9.




Figure 10 (Image Series) - False-Negative HIV Diagnostic Test (Image Series) - Figure 10 (Image Series) - False-Negative HIV Diagnostic Test
Image 10A: Test Results for Persons with HIV Infection




Figure 10 (Image Series) - False-Negative HIV Diagnostic Test
Image 10B: False-Negative Identified




Figure 11 (Image Series) - False-Positive HIV Diagnostic Test (Image Series) - Figure 11 (Image Series) - False-Positive HIV Diagnostic Test
Image 11A: Test Results for Persons without HIV




Figure 11 (Image Series) - False-Positive HIV Diagnostic Test
Image 11B: False-Positive Identified




Figure 12 Typical Timing of Serologic Markers in Persons with Acute HIV

During acute HIV (shown in shaded area), the typical pattern is positive HIV RNA, reactive HIV p24 antigen, and nonreactive anti-HIV antibodies. Note that with very early acute HIV, the HIV p24 antigen test may be nonreactive. The colored circles indicate when the test typically becomes reactive/positive (blue for HIV RNA, green for HIV p24 antigen, and purple for HIV antibody).

Illustration: David H. Spach, MD

